State of New Jersey Common Pension Fund D Has $1.76 Million Stock Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

State of New Jersey Common Pension Fund D grew its position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 40.5% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 133,111 shares of the company's stock after purchasing an additional 38,339 shares during the period. State of New Jersey Common Pension Fund D owned about 0.16% of Syndax Pharmaceuticals worth $1,760,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. abrdn plc acquired a new stake in shares of Syndax Pharmaceuticals during the fourth quarter worth $1,313,000. China Universal Asset Management Co. Ltd. raised its holdings in shares of Syndax Pharmaceuticals by 10.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 18,099 shares of the company's stock worth $239,000 after acquiring an additional 1,732 shares during the period. R Squared Ltd acquired a new stake in shares of Syndax Pharmaceuticals during the fourth quarter worth $26,000. KBC Group NV raised its holdings in shares of Syndax Pharmaceuticals by 104.8% during the fourth quarter. KBC Group NV now owns 6,954 shares of the company's stock worth $92,000 after acquiring an additional 3,559 shares during the period. Finally, Inspire Investing LLC raised its holdings in shares of Syndax Pharmaceuticals by 44.5% during the fourth quarter. Inspire Investing LLC now owns 30,792 shares of the company's stock worth $407,000 after acquiring an additional 9,484 shares during the period.

Insider Buying and Selling

In related news, CEO Michael A. Metzger sold 13,288 shares of Syndax Pharmaceuticals stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $15.50, for a total transaction of $205,964.00. Following the completion of the sale, the chief executive officer now owns 300,121 shares of the company's stock, valued at approximately $4,651,875.50. The trade was a 4.24 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Keith A. Goldan sold 3,777 shares of Syndax Pharmaceuticals stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $15.50, for a total transaction of $58,543.50. Following the completion of the sale, the chief financial officer now owns 90,746 shares of the company's stock, valued at $1,406,563. This trade represents a 4.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 21,683 shares of company stock valued at $336,087. Company insiders own 4.10% of the company's stock.

Remove Ads

Syndax Pharmaceuticals Trading Up 2.4 %

Shares of SNDX traded up $0.36 during midday trading on Friday, reaching $15.64. The stock had a trading volume of 2,576,992 shares, compared to its average volume of 2,270,811. The firm has a 50 day simple moving average of $14.19 and a 200-day simple moving average of $16.82. Syndax Pharmaceuticals, Inc. has a one year low of $12.06 and a one year high of $25.16. The firm has a market cap of $1.33 billion, a PE ratio of -4.31 and a beta of 0.90.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on SNDX. Citigroup raised their price objective on shares of Syndax Pharmaceuticals from $37.00 to $45.00 and gave the stock a "buy" rating in a report on Tuesday, November 19th. StockNews.com lowered shares of Syndax Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Saturday, November 23rd. HC Wainwright reiterated a "buy" rating and issued a $51.00 price target on shares of Syndax Pharmaceuticals in a research note on Tuesday, December 10th. Scotiabank lowered their price target on shares of Syndax Pharmaceuticals from $18.00 to $16.00 and set a "sector perform" rating on the stock in a research note on Wednesday, January 8th. Finally, The Goldman Sachs Group lifted their price target on shares of Syndax Pharmaceuticals from $30.00 to $33.00 and gave the company a "buy" rating in a research note on Thursday, November 7th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and nine have issued a buy rating to the company's stock. According to MarketBeat, Syndax Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus price target of $36.20.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).